Kayne Anderson Rudnick Investment Management LLC Sells 468 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Kayne Anderson Rudnick Investment Management LLC trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,278 shares of the biopharmaceutical company’s stock after selling 468 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $3,760,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of REGN. Pamalican Asset Management Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $4,915,000. Intact Investment Management Inc. acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $356,000. Rhenman & Partners Asset Management AB lifted its stake in Regeneron Pharmaceuticals by 11.4% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company’s stock valued at $30,956,000 after purchasing an additional 4,457 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after buying an additional 2,828 shares during the last quarter. Finally, Fagan Associates Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after acquiring an additional 3,832 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.3 %

NASDAQ REGN opened at $561.49 on Tuesday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $61.38 billion, a P/E ratio of 14.67, a PEG ratio of 2.34 and a beta of 0.44. The business has a fifty day simple moving average of $643.90 and a 200 day simple moving average of $733.36. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the company posted $11.86 earnings per share. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.63%. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Truist Financial cut their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Sanford C. Bernstein decreased their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Citigroup lowered their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, JPMorgan Chase & Co. decreased their price target on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a research note on Monday, March 31st. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $963.56.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.